Altimmune, Inc. Forecast, price target & analysts
Altimmune, Inc. Target price 2025 - Analyst rating & recommendation
Altimmune, Inc. Classifications & Recommendation:
Altimmune, Inc. Price Target
| Target Price | $22.38 |
| Price | $5.06 |
| Potential |
342.19%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Altimmune, Inc. 2026 .
The average Altimmune, Inc. target price is $22.38.
This is
342.19%
register free of charge
$28.00
453.36%
register free of charge
$12.00
137.15%
register free of charge
|
|
| A rating was issued by 10 analysts: 9 Analysts recommend Altimmune, Inc. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Altimmune, Inc. stock has an average upside potential 2026 of
342.19%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.02 | 0.00 |
| 95.35% | 85.50% | |
| EBITDA Margin | -514,650.00% | -4,122,978.05% |
| 2,565.30% | 701.12% | |
| Net Margin | -484,745.00% | -3,407,069.63% |
| 1,635.54% | 602.86% |
7 Analysts have issued a sales forecast Altimmune, Inc. 2025 . The average Altimmune, Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Altimmune, Inc. EBITDA forecast 2025. The average Altimmune, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 Altimmune, Inc. Analysts have issued a net profit forecast 2025. The average Altimmune, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.34 | -1.35 |
| 19.28% | 0.75% | |
| P/E | negative | |
| EV/Sales | 90,808.54 |
4 Analysts have issued a Altimmune, Inc. forecast for earnings per share. The average Altimmune, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Altimmune, Inc....
Current Altimmune, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 03 2025 |
| Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 18 2025 |
| Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 03 2025 |
| William Blair |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 05 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 03 2025 |
|
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Apr 02 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 18 2025 |
|
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 03 2025 |
|
Locked
William Blair:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 05 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
